北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Long-Term Efficacy and Tolerability of a Fixed-Dose Combination of Antihypertensive Agents An Open-Label Surveillance Study in China
作者: Wu, Yiqun1,2; Hu, Yonghua1,2; Tang, Xun1,2; He, Liu1,2; Ren, Tao1,2; Tao, Qiushan1,2; Qin, Xueying1,2; Sun, Ningling3; Wang, Hongyi3; Cao, Weihua1,2; Wu, Tao1,2; Zhan, Siyan1,2; Wang, Jin4; Chen, Weihua4; Li, Liming1,2
刊名: CLINICAL DRUG INVESTIGATION
发表日期: 2011
卷: 31, 期:11, 页:769-777
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: BLOOD-PRESSURE ; HYPERTENSIVE PATIENTS ; HYDROCHLOROTHIAZIDE ; AMLODIPINE ; METAANALYSIS ; MULTICENTER ; PREVENTION ; MANAGEMENT ; ADHERENCE ; ATENOLOL
英文摘要:

Background: A fixed-dose combination (FDC) of four compounds, hydrochlorothiazide 12.5 mg, triamterene 12.5 mg, dihydralazine 12.5 mg and reserpine 0.1 mg (HTDR), is widely used as an antihypertensive treatment in China. Although HTDR has been used in China for more than 30 years, there have been few comprehensive evaluations of this treatment.

Objective: The aim of this study was to investigate the long-term efficacy and tolerability of HTDR in Chinese patients with essential hypertension.

Methods: This was a 36-month, community-based, open-label surveillance study, conducted in the Huangpu District (Shanghai, China). The study was based in local primary healthcare settings. Subjects were recruited if they had essential hypertension, were aged >= 35 years at the time of enrolment, were expected to remain in the area for 3 years, and were able to provide informed consent. Patients who had secondary hypertension, myocardial infarction or stroke within 6 months of screening, impaired renal or hepatic function, history of cardiomyopathy or chronic heart failure, or were pregnant or lactating were excluded. HTDR was administered as one or two tablets per day in the morning. If necessary, additional hydrochlorothiazide was added. Blood pressure (BP) was measured at baseline and throughout the 36-month surveillance period every 3 months. Biochemical indicators (e.g. fasting blood glucose, plasma lipid parameters, plasma sodium and potassium, plasma uric acid and serum creatinine) were also measured, and adverse events were noted. BP reductions and the rate at which patients achieved BP targets (systolic BP [SBP] < 140 mmHg and diastolic BP [DBP] < 90 mmHg) throughout the period were determined. Subgroup analyses by sex and age were also conducted.

Results: A total of 1529 patients (550 male, 979 female; mean age 65.7 years) entered the study. After the 36-month treatment period, 93.1% of patients had achieved the SBP target, 97.9% had achieved the DBP target, and 92.1% had achieved both. The mean decreases in SBP and DBP were 15.3 mmHg and 9.9 mmHg, respectively. Overall, 127 adverse events in 119 patients (7.8%) occurred during the follow-up period, most of which were mild to moderate. Plasma lipid profiles were improved after 24 months of treatment. In addition, a significant increase in plasma potassium and a significant reduction in plasma uric acid were seen.

Conclusion: HTDR was found to have good long-term efficacy and tolerability in Chinese patients with essential hypertension.

语种: 英语
所属项目编号: 2001BAF03B02 ; 2006BAI01A03-(16)
项目资助者: Chinese Science &amp ; Technology (ST) Ministry
WOS记录号: WOS:000297185900003
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56835
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China
2.Peking Univ, Minist Educ, Key Lab Epidemiol, Beijing 100871, Peoples R China
3.Peking Univ, Peoples Hosp, Cardiovasc Dept, Beijing 100871, Peoples R China
4.Community Care Ctr, Shanghai, Peoples R China

Recommended Citation:
Wu, Yiqun,Hu, Yonghua,Tang, Xun,et al. Long-Term Efficacy and Tolerability of a Fixed-Dose Combination of Antihypertensive Agents An Open-Label Surveillance Study in China[J]. CLINICAL DRUG INVESTIGATION,2011,31(11):769-777.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wu, Yiqun]'s Articles
[Hu, Yonghua]'s Articles
[Tang, Xun]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wu, Yiqun]‘s Articles
[Hu, Yonghua]‘s Articles
[Tang, Xun]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace